Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities.

Biomark Res · 2025 · PMC12121208 · PMID 40437627

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.13not close (p > 0.1)

In the LUAD-like group, continuing EGFR-TKI treatment showed a trend towards longer PFS compared to discontinuation (6.2 months (95%CI, 4.4–8.0 months) vs. 3.6 months (95%CI, 1.2–6.1 months), p = 0.13).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.